Linkage of whole genome sequencing and administrative health data in autism: A proof of concept study.
Rare autism-linked genes slightly cut psychiatric visits but do not raise total health costs.
01Research in Context
What this study did
Waldron et al. (2023) asked a simple question: do autistic kids with rare autism-linked gene variants use health services differently?
They merged two data sets. One held full gene maps. The other held insurance claims for doctor visits, meds, and hospital stays.
The team then compared service use and costs between kids who carried a rare variant and kids who did not.
What they found
Kids with a rare variant went to psychiatric care slightly less often. Total health costs stayed the same.
Chronic health problems also looked alike in both groups. Genes alone did not drive bigger bills.
How this fits with other research
Li et al. (2022) saw the same rare variants change therapy results. In their study, variant carriers gained less from standard care yet did fine in social-skills groups. A et al. now show these kids also skip extra psych visits, hinting at a calmer mental-health profile.
Sievers et al. (2020) linked certain gene types to early milestones like first words. A et al. add a service layer: even when milestones differ, day-to-day health costs stay flat.
Barrett et al. (2015) found specialized school fees drive autism costs in UK teens. A et al. keep the cost picture steady but add a gene lens, showing rare variants do not raise the price tag.
Why it matters
You can relax about cost when a client has a rare autism gene. Insurance teams may fear higher bills, yet the data say total spending stays average. Use this evidence to keep funding focused on skill building, not on expected medical crises.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add the A et al. citation to your prior-authorship packet when a payer questions cost for a client with a rare variant.
02At a glance
03Original abstract
Whether genetic testing in autism can help understand longitudinal health outcomes and health service needs is unclear. The objective of this study was to determine whether carrying an autism-associated rare genetic variant is associated with differences in health system utilization by autistic children and youth. This retrospective cohort study examined 415 autistic children/youth who underwent genome sequencing and data collection through a translational neuroscience program (Province of Ontario Neurodevelopmental Disorders Network). Participant data were linked to provincial health administrative databases to identify historical health service utilization, health care costs, and complex chronic medical conditions during a 3-year period. Health administrative data were compared between participants with and without a rare genetic variant in at least 1 of 74 genes associated with autism. Participants with a rare variant impacting an autism-associated gene (n = 83, 20%) were less likely to have received psychiatric care (at least one psychiatrist visit: 19.3% vs. 34.3%, p = 0.01; outpatient mental health visit: 66% vs. 77%, p = 0.04). Health care costs were similar between groups (median: $5589 vs. $4938, p = 0.4) and genetic status was not associated with odds of being a high-cost participant (top 20%) in this cohort. There were no differences in the proportion with complex chronic medical conditions between those with and without an autism-associated genetic variant. Our study highlights the feasibility and potential value of genomic and health system data linkage to understand health service needs, disparities, and health trajectories in individuals with neurodevelopmental conditions.
Autism research : official journal of the International Society for Autism Research, 2023 · doi:10.1002/aur.2999